Rizzuto G - Search Results

1

Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.

Macaluso FS, Giuliano A, Fries W, Viola A, Abbruzzese A, Cappello M, Giuffrida E, Carrozza L, Privitera AC, Magnano A, Ferracane C, Scalisi G, Minissale MG, Giangreco E, Garufi S, Bertolami C, Cucinotta U, Graziano F, Casà A, Renna S, Teresi G, Rizzuto G, Mannino M, Maida M, Orlando A. Macaluso FS, et al. Among authors: rizzuto g. Inflamm Bowel Dis. 2023 Feb 1;29(2):217-221. doi: 10.1093/ibd/izac064. Inflamm Bowel Dis. 2023. PMID: 35385102 Free PMC article.

2

Splenic tuberculosis in a patient with Crohn's disease on infliximab: case report.

Cappello M, Randazzo C, Rizzuto G, Bonura C, Di Vita G, Galia M. Cappello M, et al. Among authors: rizzuto g. Inflamm Bowel Dis. 2010 Mar;16(3):368-70. doi: 10.1002/ibd.20998. Inflamm Bowel Dis. 2010. PMID: 19591134 No abstract available.

3

Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study.

Mocciaro F, Renna S, Orlando A, Rizzuto G, Sinagra E, Orlando E, Cottone M. Mocciaro F, et al. Among authors: rizzuto g. J Crohns Colitis. 2012 Jul;6(6):681-6. doi: 10.1016/j.crohns.2011.11.021. Epub 2012 Jan 13. J Crohns Colitis. 2012. PMID: 22398101

4

Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center.

Orlando A, Renna S, Rizzuto G, Orlando E, Affronti M, Cottone M. Orlando A, et al. Among authors: rizzuto g. Clin Gastroenterol Hepatol. 2016 Jun;14(6):914. doi: 10.1016/j.cgh.2015.12.022. Epub 2015 Dec 18. Clin Gastroenterol Hepatol. 2016. PMID: 26707682 No abstract available.

5

Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.

Macaluso FS, Criscuoli V, Orlando E, Rizzuto G, Renna S, Cottone M, Orlando A. Macaluso FS, et al. Among authors: rizzuto g. Aliment Pharmacol Ther. 2016 May;43(9):1019-20. doi: 10.1111/apt.13565. Aliment Pharmacol Ther. 2016. PMID: 27040168 No abstract available.

6

Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis.

Renna S, Orlando E, Macaluso FS, Maida M, Affronti M, Giunta M, Sapienza C, Rizzuto G, Orlando R, Dimarco M, Cottone M, Orlando A. Renna S, et al. Among authors: rizzuto g. Aliment Pharmacol Ther. 2016 Aug;44(3):310-1. doi: 10.1111/apt.13692. Aliment Pharmacol Ther. 2016. PMID: 27375103 No abstract available.

7

Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study.

Orlando A, Renna S, Mocciaro F, Cappello M, Giunta M, Mendolaro M, Mazza M, Rizzuto G, Orlando E, Affronti M, Dimarco M, Di Mitri R, Craxì A, Cottone M. Orlando A, et al. Among authors: rizzuto g. Dig Liver Dis. 2016 Nov;48(11):1314-1317. doi: 10.1016/j.dld.2016.07.019. Epub 2016 Aug 9. Dig Liver Dis. 2016. PMID: 27578212

8

Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.

Macaluso FS, Maida M, Renna S, Orlando E, Affronti M, Sapienza C, Dimarco M, Orlando R, Rizzuto G, Cottone M, Orlando A. Macaluso FS, et al. Among authors: rizzuto g. Dig Liver Dis. 2017 Feb;49(2):157-162. doi: 10.1016/j.dld.2016.10.001. Epub 2016 Oct 14. Dig Liver Dis. 2017. PMID: 27876682

9

The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.

Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, DʼIncà R, Lionetti P, Cantoro L, Fries W, Annunziata ML, Costa F, Terpin MM, Biancone L, Cortelezzi CC, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, Andriulli A, Massari A, Lorenzon G, Ghione S, Kohn A, Ventra A, Annese V; PROSIT-BIO Cohort. Fiorino G, et al. Among authors: rizzuto g. Inflamm Bowel Dis. 2017 Feb;23(2):233-243. doi: 10.1097/MIB.0000000000000995. Inflamm Bowel Dis. 2017. PMID: 28092307

10

Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience.

Macaluso FS, Renna S, Maida M, Dimarco M, Sapienza C, Affronti M, Orlando E, Rizzuto G, Orlando R, Ventimiglia M, Cottone M, Orlando A. Macaluso FS, et al. Among authors: rizzuto g. Scand J Gastroenterol. 2017 Sep;52(9):981-987. doi: 10.1080/00365521.2017.1333626. Epub 2017 May 29. Scand J Gastroenterol. 2017. PMID: 28554266

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

109 results

Search Page

Filters